Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy.

ABSTRACT:

Background/aim

To evaluate relationships between subretinal fluid (SRF), macular atrophy (MA) and visual outcomes in ranibizumab-treated neovascular age-related macular degeneration (nAMD).

Methods

This post hoc HARBOR trial (NCT00891735) analysis included ranibizumab-treated (0.5 or 2.0 mg, monthly or as-needed, all treatment arms pooled) eyes with nAMD and baseline (screening, baseline and week 1) SRF. SRF presence, SRF thickness (0, >0-50, >50-100 and >100 µm) and subretinal fluid volume (SRFV) were determined by spectral domain optical coherence tomography (SD-OCT). Best-corrected visual acuity (BCVA) was assessed. MA was identified using fluorescein angiograms and colour fundus photographs, as well as SD-OCT.

Results

Seven hundred eighty-five of 1097 eyes met ana

SUBMITTER: Zarbin MA 

PROVIDER: S-EPMC9606534 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature